Deep-learning nomogram reproduced 3D treated volume for prostate HDR brachytherapy QA
A 3D deep-learning nomogram predicted the clinical prescription isodose with high spatial agreement, adding geometry-aware verification to post-plan QA.
A 3D deep-learning nomogram predicted the clinical prescription isodose with high spatial agreement, adding geometry-aware verification to post-plan QA.
Durvalumab after CRT improved long-term outcomes in stage III NSCLC, while dose escalation above 66 Gy showed only exploratory intrathoracic benefit.
44 Gy in 20 fractions shortened cervical cancer treatment by seven days but showed numerically more severe late GI toxicity.
Spectral CT adds quantitative tissue information across planning, particle range estimation and adaptive imaging, but prospective outcome evidence remains limited.
Routine DIBH respiratory traces predicted fraction-level mean heart dose deviation, but LAD dose estimates were substantially less reliable.
No contralateral neck recurrences occurred among 43 N2b patients receiving unilateral RT despite frequent high ipsilateral nodal burden.
Relative oxygen extraction declined across irradiated prostate and tumor tissue during five-fraction MRgSBRT, with the largest early changes.
ESTRO’s review supports selected single-fraction SBRT applications while highlighting major evidence and toxicity gaps in abdominal tumors.
Semi-automated FDG PET/CT produced more reproducible nodal target volumes than manual MRI and identified all metastatic nodes consistently.
After 50 Gy in five fractions, local progression was 15% at one year, while distant progression remained the dominant failure pattern.
Higher tumor SMAD4 was associated with better disease-free survival and lower distant metastatic risk after resection and adjuvant chemoradiotherapy.
In 39 patients, carbon-ion RT achieved 91.2% two-year local control without grade ≥3 acute radiation-associated toxicity.
After prior TURP, focal SIB was not significantly associated with severe late GU toxicity, while repeated TURP consistently identified higher-risk patients.
Across 1,378 adaptive fractions, 4.6% had shifts above 6 mm and longer adaptation times were linked to greater prostate displacement.
Retrospective DL-MAR studies achieved dose errors below 3%, but no prospective clinical validation has yet been reported.